JP2010534684A5 - - Google Patents

Download PDF

Info

Publication number
JP2010534684A5
JP2010534684A5 JP2010518431A JP2010518431A JP2010534684A5 JP 2010534684 A5 JP2010534684 A5 JP 2010534684A5 JP 2010518431 A JP2010518431 A JP 2010518431A JP 2010518431 A JP2010518431 A JP 2010518431A JP 2010534684 A5 JP2010534684 A5 JP 2010534684A5
Authority
JP
Japan
Prior art keywords
seq
composition according
amino acid
acid sequence
cationic peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010518431A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010534684A (ja
JP5401457B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/071350 external-priority patent/WO2009015385A1/en
Publication of JP2010534684A publication Critical patent/JP2010534684A/ja
Publication of JP2010534684A5 publication Critical patent/JP2010534684A5/ja
Application granted granted Critical
Publication of JP5401457B2 publication Critical patent/JP5401457B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010518431A 2007-07-26 2008-07-28 抗菌ペプチド、組成物及びその使用方法 Expired - Fee Related JP5401457B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95205907P 2007-07-26 2007-07-26
US60/952,059 2007-07-26
PCT/US2008/071350 WO2009015385A1 (en) 2007-07-26 2008-07-28 Antimicrobial peptide, compositions , and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013222846A Division JP5965884B2 (ja) 2007-07-26 2013-10-28 抗菌ペプチド、組成物及びその使用方法

Publications (3)

Publication Number Publication Date
JP2010534684A JP2010534684A (ja) 2010-11-11
JP2010534684A5 true JP2010534684A5 (https=) 2011-06-02
JP5401457B2 JP5401457B2 (ja) 2014-01-29

Family

ID=40281862

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2010518431A Expired - Fee Related JP5401457B2 (ja) 2007-07-26 2008-07-28 抗菌ペプチド、組成物及びその使用方法
JP2013222846A Expired - Fee Related JP5965884B2 (ja) 2007-07-26 2013-10-28 抗菌ペプチド、組成物及びその使用方法
JP2016132290A Pending JP2017002057A (ja) 2007-07-26 2016-07-04 抗菌ペプチド、組成物及びその使用方法
JP2018153719A Active JP6722241B2 (ja) 2007-07-26 2018-08-17 抗菌ペプチド、組成物及びその使用方法
JP2020105975A Pending JP2020169190A (ja) 2007-07-26 2020-06-19 抗菌ペプチド、組成物及びその使用方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2013222846A Expired - Fee Related JP5965884B2 (ja) 2007-07-26 2013-10-28 抗菌ペプチド、組成物及びその使用方法
JP2016132290A Pending JP2017002057A (ja) 2007-07-26 2016-07-04 抗菌ペプチド、組成物及びその使用方法
JP2018153719A Active JP6722241B2 (ja) 2007-07-26 2018-08-17 抗菌ペプチド、組成物及びその使用方法
JP2020105975A Pending JP2020169190A (ja) 2007-07-26 2020-06-19 抗菌ペプチド、組成物及びその使用方法

Country Status (24)

Country Link
US (1) US8623811B2 (https=)
EP (3) EP2178549B1 (https=)
JP (5) JP5401457B2 (https=)
KR (4) KR101717275B1 (https=)
CN (2) CN101842107B (https=)
AU (1) AU2008278593B2 (https=)
BR (3) BRPI0813627B1 (https=)
CA (1) CA2694046C (https=)
CO (1) CO6260098A2 (https=)
CR (1) CR11239A (https=)
CY (2) CY1118503T1 (https=)
DK (2) DK2178549T3 (https=)
ES (2) ES2609914T3 (https=)
HR (1) HRP20161722T1 (https=)
HU (1) HUE031136T2 (https=)
IL (3) IL203173A (https=)
LT (1) LT2178549T (https=)
MX (1) MX2010000916A (https=)
NZ (1) NZ582459A (https=)
PL (1) PL2178549T3 (https=)
PT (2) PT3120862T (https=)
SG (1) SG188128A1 (https=)
SI (1) SI2178549T1 (https=)
WO (1) WO2009015385A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ598159A (en) * 2006-12-29 2013-08-30 Revance Therapeutics Inc Transport molecules using reverse sequence hiv-tat polypeptides
CN101842107B (zh) * 2007-07-26 2014-04-23 雷文斯治疗公司 抗微生物肽,组合物和使用方法
US8080518B2 (en) * 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
PL2271670T3 (pl) 2008-03-14 2015-05-29 Allergan Inc Testy aktywności serotypu A toksyny botulinowej oparte na immunologii
AU2009332947C1 (en) 2008-12-31 2019-01-03 Revance Therapeutics, Inc. Injectable botulinum toxin formulations
KR101959234B1 (ko) 2009-04-01 2019-03-18 레반스 테라퓨틱스, 아이엔씨. 혈관 과민반응과 관련된 피부질환을 치료하기 위한 방법 및 조성물
EP3682895A1 (en) 2009-06-10 2020-07-22 NoNO Inc. Co-administration of an agent linked to a tat-internalization peptide with a mast cell degranulation inhibitor
EP2445521A4 (en) 2009-06-25 2015-08-26 Revance Therapeutics Inc ALBUMINE-FREE BOTULINUM TOXIN FORMULATIONS
US10022083B2 (en) 2011-06-02 2018-07-17 Abdulmohsen E. A. H. Al-Terki Multiple oral and nasal surgical procedures method and kit
US8387798B1 (en) 2012-04-27 2013-03-05 Abdulmohsen E. A. H. Al-Terki Mutiple oral and nasal surgical procedures method and kit
FR2997304B1 (fr) 2012-10-26 2017-07-07 Isp Investments Inc Utilisation d’un extrait de lin, en tant qu’agent actif activateur de la synthese de peptides antimicrobiens
CA2889833A1 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
US20140242110A1 (en) * 2013-02-28 2014-08-28 Dt Scimed, Llc Dose, localization, and formulation of botulinum toxins in skin and muscle
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11446236B2 (en) 2015-08-05 2022-09-20 Cmpd Licensing, Llc Topical antimicrobial compositions and methods of formulating the same
US11684567B2 (en) 2015-08-05 2023-06-27 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11793783B2 (en) 2015-08-05 2023-10-24 Cmpd Licensing, Llc Compositions and methods for treating an infection
EP4115897A1 (en) * 2015-09-17 2023-01-11 Contrafect Corporation Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby
US10105381B2 (en) * 2016-05-23 2018-10-23 Cmpd Licensing, Llc Compositions and methods for treating an infection
US10144767B2 (en) * 2016-08-18 2018-12-04 Board Of Regents Of The University Of Nebraska Anti-microbial peptides and coatings
AU2017360346B2 (en) * 2016-11-21 2023-11-23 Eirion Therapeutics, Inc. Transdermal delivery of large agents
EP3675900A4 (en) 2017-08-28 2021-05-05 Revance Therapeutics, Inc. Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders
CN107556374B (zh) * 2017-08-30 2020-02-07 四川大学 唾液富脯蛋白仿生防龋功能多肽、其衍生物和盐及其应用
CN107353334B (zh) * 2017-08-30 2020-02-07 四川大学 基于唾液富酪蛋白的仿生防龋多肽、其衍生物和盐及应用
JP7266202B2 (ja) * 2018-02-19 2023-04-28 株式会社ファンケル 化粧料及び抗炎症剤
US20230149333A1 (en) * 2020-04-08 2023-05-18 Amicrobe, Inc. Compositions and uses of locally applied synthetic amino acid polymers for prevention and treatment of viral infections
AU2024342863A1 (en) 2023-09-15 2026-04-09 Revance Therapeutics, Inc. Serial treatment with botulinum toxin for cervical dystonia
WO2025064729A1 (en) 2023-09-19 2025-03-27 Revance Therapeutics, Inc. Treatment with botulinum toxin in patients in need of a rapid onset cosmetic effect and smoother skin appearance
WO2025072381A1 (en) 2023-09-25 2025-04-03 Revance Therapeutics, Inc. Methods for determining influence of carrier peptide on the binding of a therapeutic protein to a cell membrane

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744166A (en) 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
EP0637247B1 (en) * 1992-04-23 1998-08-19 Allelix Biopharmaceuticals Inc. Treatment of herpesvirus infection
CA2135642C (en) 1992-08-21 1999-12-14 James G. Barsoum Tat-derived transport polypeptides
CA2152373C (en) * 1993-10-22 1998-12-15 Michael Twist (Deceased) Treatment of cytomegalovirus infection
ES2332905T3 (es) 1993-12-28 2010-02-15 Allergan, Inc. Uso del componente neurotoxico de la toxina botulinica para el tratamiento de trastornos de musculos lisos.
US6232295B1 (en) 1994-10-12 2001-05-15 Jon Faiz Kayyem Cell-specific contrast agent and gene delivery vehicles
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
JP3860838B2 (ja) 1995-08-23 2006-12-20 ユニバーシティー オブ ブリティッシュ コロンビア 抗微生物性陽イオン性ペプチドおよびそのスクリーニング方法
US6043218A (en) * 1996-10-22 2000-03-28 Medical University Of South Carolina Positively charged non-natural amino acids, methods of making thereof, and use thereof in peptides
GB9623051D0 (en) 1996-11-06 1997-01-08 Schacht Etienne H Delivery of DNA to target cells in biological systems
CA2314267A1 (en) 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
CN1281512A (zh) 1997-12-12 2001-01-24 昂尼克斯药物公司 p53+肿瘤细胞的选择性杀伤和诊断
EP1128844B1 (en) 1998-10-27 2006-01-04 Mayo Foundation For Medical Education And Research Botulinum toxins for enhancing wound healing
JP2002531113A (ja) 1998-12-10 2002-09-24 ワシントン大学 蛋白質の形質導入システムおよびその使用法
JP2002533379A (ja) 1998-12-23 2002-10-08 イデア アクチェンゲゼルシャフト 生体内における局所的に非侵襲性である用途のための改善された製剤
US7056656B1 (en) 1999-01-25 2006-06-06 University Of Medicine And Dentistry Of New Jersey Tat-derived oligourea and its method of production and use in high affinity and specific binding HIV-1 TAR RNA
US20030236214A1 (en) 1999-06-09 2003-12-25 Wolff Jon A. Charge reversal of polyion complexes and treatment of peripheral occlusive disease
US7008924B1 (en) 1999-07-21 2006-03-07 Amgen, Inc. VGF fusion polypeptides
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6544548B1 (en) 1999-09-13 2003-04-08 Keraplast Technologies, Ltd. Keratin-based powders and hydrogel for pharmaceutical applications
US6844324B1 (en) 1999-11-12 2005-01-18 Massachusetts Institute Of Technology Modular peptide mediated intracellular delivery system and uses therefore
US20030118598A1 (en) 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US6670322B2 (en) 2000-06-01 2003-12-30 Wisconsin Alumni Research Foundation Method of targeting pharmaceuticals to motor neurons
US20040220100A1 (en) 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
EP1301213B1 (en) 2000-07-21 2017-01-18 ReVance Therapeutics, Inc. Multi-component biological transport systems
US20030215412A1 (en) 2000-07-21 2003-11-20 Essentia Biosystems, Inc. Induction of hair growth with vascular endothelial growth factor
US6696038B1 (en) 2000-09-14 2004-02-24 Expression Genetics, Inc. Cationic lipopolymer as biocompatible gene delivery agent
US20020127247A1 (en) 2000-11-17 2002-09-12 Allergen Sales, Inc. Modified clostridial neurotoxins with altered biological persistence
MXPA03007358A (es) 2001-02-16 2004-12-13 Cellgate Inc Transportadores que contienen porciones de arginina separadas.
CA2446458A1 (en) * 2001-05-09 2002-11-14 Yale University Toll/interleukin-1 receptor adaptor protein (tirap)
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
AU2002359679B2 (en) 2001-12-11 2009-01-08 Cellgate, Inc. Guanidinium transport reagents and conjugates
WO2003072049A2 (en) 2002-02-21 2003-09-04 Essentia Biosystems, Inc. Induction of hair growth with vascular endothelial growth factor
US20030215395A1 (en) 2002-05-14 2003-11-20 Lei Yu Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
JP4154218B2 (ja) * 2002-11-27 2008-09-24 寛紀 高麗 新規抗菌性ポリペプチドとその利用
IL153557A0 (en) * 2002-12-19 2003-07-06 Yitzchak Hillman Antibodies and antagonists to antimicrobial peptides for the purpose of treating, inhibiting and preventing auto immune diseases
AU2003288507A1 (en) * 2002-12-19 2004-07-14 Yitzchak Hillman Disease treatment via antimicrobial peptide inhibitors
MXPA05008156A (es) * 2003-02-01 2005-09-30 Neuralab Ltd Inmunizacion activa para generar anticuerpos para beta-a soluble.
WO2004084805A2 (en) 2003-03-19 2004-10-07 The J. David Gladstone Institutes Acetylated tat polypeptides and methods of use thereof
US7125842B2 (en) * 2003-04-07 2006-10-24 Canbas Co. Ltd. Anti-fungal compounds and methods of use
TW200526690A (en) * 2003-09-12 2005-08-16 Univ British Columbia Effectors of innate immunity determination
JP2005120050A (ja) * 2003-10-20 2005-05-12 Toagosei Co Ltd 新規抗菌性ペプチドとその利用
CA2558676C (en) 2004-03-03 2019-04-16 Essentia Biosystems, Inc. Compositions and methods for topical diagnostic and therapeutic transport
CN1946431B (zh) 2004-03-03 2011-12-07 雷文斯治疗公司 用于肉毒毒素的局部施用和透皮递送的组合物和方法
PL1778720T3 (pl) 2004-08-18 2011-03-31 Novabiotics Ltd Antybakteryjne peptydy zawierające wzór zawierający argininę i/lub lizynę
EP2116603A3 (en) 2004-11-12 2010-02-17 The University Of British Columbia Antimicrobial peptides
EP1656951A1 (en) * 2004-11-12 2006-05-17 Xigen S.A. Conjugates with enhanced cell uptake activity
EP1661912A1 (en) 2004-11-29 2006-05-31 Xigen S.A. Fusion protein comprising a BH3-domain of a BH3-only protein
JP4730584B2 (ja) * 2004-12-06 2011-07-20 東亞合成株式会社 抗菌ペプチド及びその利用
JP2006238751A (ja) * 2005-03-02 2006-09-14 Toagosei Co Ltd ベロ毒素結合性を有する抗菌ペプチド及びその利用
CN101160318A (zh) 2005-03-03 2008-04-09 雷文斯治疗公司 用于局部施用和经皮肤递送寡肽的组合物和方法
SG160357A1 (en) 2005-03-03 2010-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
JP5388568B2 (ja) 2005-03-30 2014-01-15 ルバンス セラピュティックス インク. ざ瘡を治療するための組成物及び方法
NZ568216A (en) 2005-11-17 2012-09-28 Revance Therapeutics Inc Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
NZ598159A (en) 2006-12-29 2013-08-30 Revance Therapeutics Inc Transport molecules using reverse sequence hiv-tat polypeptides
JP2010514781A (ja) 2006-12-29 2010-05-06 ルバンス セラピュティックス インク. Hiv−tatに由来するポリペプチド断片を用いて安定化されるボツリヌス毒素を局所適用及び経皮送達する組成物及び方法
CN101842107B (zh) * 2007-07-26 2014-04-23 雷文斯治疗公司 抗微生物肽,组合物和使用方法
AU2009332947C1 (en) 2008-12-31 2019-01-03 Revance Therapeutics, Inc. Injectable botulinum toxin formulations

Similar Documents

Publication Publication Date Title
JP2010534684A5 (https=)
RU2016146198A (ru) Терапевтические dll4-связывающие белки
JP2011136981A5 (https=)
JP2013507132A5 (https=)
JP2012034696A5 (https=)
JP2010265269A5 (https=)
JP2007045829A5 (https=)
JP2017048194A5 (https=)
JP2015513533A5 (https=)
JP2013510581A5 (https=)
JP2011155981A5 (https=)
WO2007149542A3 (en) Antimicrobial kinocidin compositions and methods of use
WO2007122581A3 (en) Compositions and kits of phenylephrine
JP2009225798A5 (https=)
CN102036649A8 (zh) 精氨酸盐及其治疗口腔疾病的用途
JP2011177189A5 (https=)
NZ612161A (en) Radiolabled her2 binding peptides
EP2455461A3 (en) Lipase variants for pharmaceutical use
WO2008011335A3 (en) Metal binding compounds, metal binding compositions, and their uses
JP2009504138A5 (https=)
EA201001014A1 (ru) Фармацевтически приемлемые соли метил (3-{[[3-(6-амино-2-бутокси-8-оксо-7,8-дигидро-9h-пурин-9-ил)пропил](3-морфолин-4-илпропил)амино]метил}фенил)ацетата и их применение в терапии
WO2013000922A9 (en) Ccr2 antagonist peptides
DE602005008996D1 (de) Radiofluorierte peptide
TW200942524A (en) Novel aminomethyl benzene derivatives
JP2015533791A5 (https=)